amatuximab

Ligand id: 7750

Name: amatuximab

References
1. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. (2010)
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Clin. Cancer Res., 16 (24): 6132-8. [PMID:21037025]
2. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L et al.. (2007)
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Cancer Immun., 7: 20. [PMID:18088084]
3. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P et al.. (2014)
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Clin. Cancer Res., 20 (23): 5927-36. [PMID:25231400]
4. Ma J, Tang WK, Esser L, Pastan I, Xia D. (2012)
Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009.
Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 68 (Pt 8): 950-3. [PMID:22869130]
5. Tang Z, Qian M, Ho M. (2013)
The role of mesothelin in tumor progression and targeted therapy.
Anticancer Agents Med Chem, 13 (2): 276-80. [PMID:22721387]